Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Stock Information for Helport AI Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Helport AI Limited

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.